西罗莫司洗脱支架与血管内近距离放射疗法治疗裸金属支架内再狭窄的疗效比较:SISR随机试验

来源 :世界核心医学期刊文摘(心脏病学分册) | 被引量 : 0次 | 上传用户:jhh760606
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Context: Although vascular brachytherapy is the only approved therapy for restenosis following bare-metal stent implantation, drug-eluting stents are now being used. Data on the relative merits of each are limited. Objective: To determine the safety and efficacy of the sirolimus-eluting stent compared with vascular brachytherapy for the treatment of patients with restenosis within a bare metal stent. Design, Setting, and Patients: Prospective, multicenter, randomized trial of 384 patients with in-stent restenosis who were enrolled between February 2003 and July 2004 at 26 academic and community medical centers. Data presented represent all follow-up as of June 30, 2005. Interventions: Vascular brachytherapy(n=125) or the sirolimus-eluting stent(n=259). Main Outcome Measure: Target vessel failure(cardiac death, myocardial infarction, or target vessel revascularization)at 9 months postprocedure. Results: Baseline patient characteristics were well matched. Lesion length was similar between vascular brachytherapy and sirolimus-eluting stent patients(mean [SD], 16.76 [8.55] mm vs 17.22 [7.97] mm, respectively; P=.61). Procedural success was 99.2% (124/125) in the vascular brachytherapy group and 97.3% (250/257) in the sirolimus-eluting stent group(P=.28). The rate of target vessel failure was 21.6% (27/125) with vascular brachytherapy and 12.4% (32/259) with the sirolimus-eluting stent(relative risk [RR], 1.7; 95% confidence interval [CI], 1.1-2.8; P=.02). Target lesion revascularization was required in 19.2% (24/125) of the vascular brachytherapy group and 8.5% (22/259) of the sirolimus-eluting stent group(RR, 2.3 [95% CI, 1.3-3.9]; P=.004). At follow-up angiography, the rate of binary angiographic restenosis for the analysis segment was 29.5% (31/105) for the vascular brachytherapy group and 19.8% (45/227) for the sirolimus-eluting stent group(RR, 1.5 [95% CI, 1.0-2.2]; P=.07). Compared with the vascular brachytherapy group, minimal lumen diameter was larger in the sirolimus-eluting stent group at 6-month follow-up(mean [SD], 1.52 [0.63] mm vs 1.80 [0.63] mm; P< .001), reflecting greater net lumen gain in the analysis segment(0.68 [0.60] vs 1.0 [0.61] mm; P< .001) due to stenting and no edge restenosis. Conclusion: Sirolimus-eluting stents result in superior clinical and angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis within a bare-metal stent. Trial Registration: ClinicalTrials.gov Identifier: NCT00231257. Context: Although vascular brachytherapy is the only approved therapy for restenosis following bare-metal stent implantation, drug-eluting stents are now being used. Objective: To determine the safety and efficacy of the sirolimus- eluting stent compared with vascular brachytherapy for the treatment of patients with restenosis within a bare metal stent. Design, Setting, and Patients: Prospective, multicenter, randomized trial of 384 patients with in-stent restenosis who were enrolled between February 2003 and July 2004 at Data presented represent all follow-up as of June 30, 2005. Interventions: Vascular brachytherapy (n = 125) or the sirolimus-eluting stent (n = 259). Main Outcome Measure: Target vessel failure ( cardiac death, myocardial infarction, or target vessel revascularization) at 9 months postprocedure. Results: Baseline patient characteristics were well matched. nural brachytherapy and sirolimus-eluting stent patients (mean [SD], 16.76 [8.55] mm vs 17.22 [7.97] mm, respectively; P = .61). Procedural success was 99.2% (124/125) in the vascular brachytherapy group and rate of target vessel failure was 21.6% (27/125) with vascular brachytherapy and 12.4% (32/259) with the sirolimus (P = .28) and 97.3% (250/257) in the sirolimus-eluting stent group -eluting stent (relative risk [RR], 1.7; 95% confidence interval [CI], 1.1-2.8; P = .02). Target lesion revascularization was required in 19.2% (24/125) of the vascular brachytherapy group and 8.5 % Follow-up angiography, the rate of binary angiographic restenosis for the analysis segment was% (22/259) of the sirolimus-eluting stent group (RR, 2.3 [95% CI, 1.3-3.9]; P = 29.5% (31/105) for the vascular brachytherapy group and 19.8% (45/227) for the sirolimus-eluting stent group (RR, 1.5 [95% CI, 1.0-2.2]; P = .07) vascular brachytherapy group, minimal lumen diameter was larger in the sirolimus-eluting stent group at 6-month follow-up at mean [SD], 1.52 [0.63] mm vs 1.80 [0.63] mm; P <.001) vs 1.0 [0.61] mm; P <.001) due to stenting and no edge restenosis. Conclusion: Sirolimus-eluting stents result in superior clinical and angiographic outcomes compared with vascular brachytherapy for the treatment of restenosis within a bare-metal stent. Trial Registration: ClinicalTrials.gov Identifier: NCT00231257.
其他文献
东盟国家的旅游业以高于世界平均增长率的速度发展,而生态旅游成为东盟国家新的经济增长点,本文介绍了东盟国家的生态旅游现状,并对东盟国家的生态旅游现状做了分析。 Touri
文章以电子邮件为对象,基于双重进入许可方式,构建了一个电子政务个性化信息服务模型。在此基础之上,本文深入分析了电子政务个性化信息服务中的用户建模和个性化推荐,并对电
歌曲,是一种美的艺术、感情的艺术,它可以陶冶人的性情、净化人的心灵、提高人的素养。歌曲,几乎人人爱唱,尤其是少年儿童,他们活泼好动,对歌曲也有莫大的兴趣。在小学英语教
第5次反“围剿”失败后,闽东进入了艰苦卓绝的三年游击战时期,洋面山会议是闽东特委在反“清剿”斗争中由叶飞主持召开的一次重要会议。谨以此文纪念叶飞将军百年诞辰。1935
在说话或写文章时,为了突出说话人的语言信息,给对方以强烈的印象和感受,我们常会用到强调结构。该句型可以用来强调除谓语动词以外的任何句子成分。但是对该句型的考查往往
海绵城市建设将是中国未来新型城镇化的必然要求,也是城市建设的过程中,中国需要加强和逐步落实的一项重要任务。作为中间环节的实现一般的规则和条例的指导,很少反映海绵城
Karst cave tourism plays an important role in the overall tourism of Zhejiang Province,China.In analyzing the current status of karst cave tourism resources,it
有一首诞生在66年前威海保卫战中的战地军歌,如今在孩子们中传唱。听到这些充满童声的歌喉唱出当年那带着战火硝烟的旋律,就想起当年这首战地军歌酝酿、创作、唱响的情境。19
开国将军谢振华的遗孀王煜正在家中养病,自从谢振华离世后,王煜的身体一直不好,孩子们嘘寒问暖,孝敬有加。但王煜的口中还是常常念叨:“爱英说来看我,什么时候回来呀?”爱英叫冯爱英,是谢振华夫妇收养的孩子。  今年春节刚过,冯爱英回来了:“阿姨,我来看您,来尽孝,回来陪您住一段时间!”王煜听见这样的话,笑着笑着,眼泪就溢出了眼眶……  谢振华上世纪70年代出任山西省委书记时,一天中午,一名自称在抗日战争
昭通市依托红色扎西教学基地开展党性教育和群众路线教育,充分发挥红色资源的教育感召作用,通过瞻仰革命遗址、体验红军生活、重走长征路等方式,在实地接受革命传统教育过程